Cost savings associated with the adoption of lower-dose everolimus in patients with advanced neuroendocrine tumors

Background: Everolimus is effective in advanced neuroendocrine tumors (NETs) but is associated with substantial toxicity and high long-term costs. Real-world data suggest that lower doses (≤6 mg/day) achieve comparable efficacy with reduced toxicity compared with standard-dose therapy. This study ai...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	G.R. de Almeida, R.P. Riechelmann, A.B. Brito, R.G. Taboada, A.L.M. da Silva, R.F. Weschenfelder, A.P.B.S. Etges
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2026-06-01
Sarja:	ESMO Gastrointestinal Oncology
Aiheet:	cost minimization everolimus neuroendocrine tumors economic analysis microcosting
Linkit:	http://www.sciencedirect.com/science/article/pii/S2949819826000373
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!